H.C. Wainwright analyst Ed Arce raised the firm’s price target on Unicycive Therapeutics (UNCY) to $7.50 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm views 2025 as a “likely transformational year” for Unicycive and the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue